BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
37.533 EUR
-0.44 (-1.15%)
We assign a fundamental rating of 5 out of 10 to BRM. BRM was compared to 54 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
In the past year BRM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
Each year in the past 5 years BRM had a positive operating cash flow.
1.2 Ratios
BRM has a Return On Assets of 5.33%. This is comparable to the rest of the industry: BRM outperforms 51.85% of its industry peers.
BRM has a better Return On Equity (28.96%) than 81.48% of its industry peers.
With a decent Return On Invested Capital value of 15.09%, BRM is doing good in the industry, outperforming 77.78% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 14.71%.
The last Return On Invested Capital (15.09%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 15.09% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
The Profit Margin of BRM (10.58%) is comparable to the rest of the industry.
BRM has a better Operating Margin (30.27%) than 79.63% of its industry peers.
BRM's Operating Margin has declined in the last couple of years.
The Gross Margin of BRM (73.92%) is better than 66.67% of its industry peers.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
BRM has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BRM has less shares outstanding
Compared to 1 year ago, BRM has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.01 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.01, BRM is doing worse than 64.81% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.37, which is a good value as it means it would take BRM, 3.37 years of fcf income to pay off all of its debts.
BRM has a Debt to FCF ratio (3.37) which is in line with its industry peers.
BRM has a Debt/Equity ratio of 2.56. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.56, BRM is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.01 |
ROIC/WACC1.97
WACC7.65%
2.3 Liquidity
A Current Ratio of 1.21 indicates that BRM should not have too much problems paying its short term obligations.
BRM's Current ratio of 1.21 is on the low side compared to the rest of the industry. BRM is outperformed by 61.11% of its industry peers.
BRM has a Quick Ratio of 1.11. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a Quick ratio of 1.11. This is in the better half of the industry: BRM outperforms 70.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 391.24%, which is quite impressive.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
Looking at the last year, BRM shows a small growth in Revenue. The Revenue has grown by 2.57% in the last year.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
The Earnings Per Share is expected to grow by 36.11% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -4.99% on average over the next years.
EPS Next Y477.64%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue Next Year-1.12%
Revenue Next 2Y-4.71%
Revenue Next 3Y-3.48%
Revenue Next 5Y-4.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.45, the valuation of BRM can be described as very cheap.
Based on the Price/Earnings ratio, BRM is valued cheaper than 94.44% of the companies in the same industry.
When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (27.34), we can say BRM is valued rather cheaply.
BRM is valuated cheaply with a Price/Forward Earnings ratio of 7.14.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 92.59% of the companies listed in the same industry.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.45 | ||
| Fwd PE | 7.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaper than 92.59% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 96.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.06 | ||
| EV/EBITDA | 5.91 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 73.61% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.04%
EPS Next 3Y73.61%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.55%, which is a nice return.
BRM's Dividend Yield is rather good when compared to the industry average which is at 3.04. BRM pays more dividend than 94.44% of the companies in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.55% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
98.12% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
FRA:BRM (10/14/2025, 1:00:00 PM)
37.533
-0.44 (-1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap76.40B
Analysts67.27
Price Target44.24 (17.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.55% |
Yearly Dividend2.09
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-2.11%
PT rev (3m)-9.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.48%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-1.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.86%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)2.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.45 | ||
| Fwd PE | 7.14 | ||
| P/S | 1.85 | ||
| P/FCF | 6.06 | ||
| P/OCF | 5.56 | ||
| P/B | 5.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.91 |
EPS(TTM)5.82
EY15.51%
EPS(NY)5.26
Fwd EY14.01%
FCF(TTM)6.19
FCFY16.49%
OCF(TTM)6.75
OCFY17.99%
SpS20.26
BVpS7.4
TBVpS-10.92
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 15.09% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 95.64% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-16.88%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.01 |
F-Score7
WACC7.65%
ROIC/WACC1.97
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y477.64%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.12%
Revenue Next 2Y-4.71%
Revenue Next 3Y-3.48%
Revenue Next 5Y-4.99%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%